Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for the Collection of Quantitative Data on Tobacco Products and Communications, 6190-6192 [2018-02852]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
6190
Federal Register / Vol. 83, No. 30 / Tuesday, February 13, 2018 / Notices
Devices News & Events—Workshops &
Conferences calendar at https://
www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
default.htm. (Select this public
workshop from the posted events list.)
Please provide complete contact
information for each attendee, including
name, title, affiliation, address, email,
and telephone.
Registration is free and based on
space availability, with priority given to
early registrants. Persons interested in
attending this public workshop must
register by April 20, 2018, by 4 p.m.
Eastern Time. Early registration is
recommended because seating is
limited; therefore, FDA may limit the
number of participants from each
organization. Registrants will receive
confirmation when they have been
accepted. If time and space permit,
onsite registration on the day of the
public workshop will be provided
beginning at 7:30 a.m. We will let
registrants know if registration closes
before the day of the public workshop.
If you need special accommodations
due to a disability, please contact Susan
Monahan, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5231, Silver Spring,
MD 20993–0002, 301–796–5661, email:
Susan.Monahan@fda.hhs.gov, no later
than April 16, 2018.
Streaming Webcast of the Public
Workshop: This public workshop will
also be webcast. The webcast link will
be available on the registration web page
after April 20, 2018. Organizations are
requested to register all participants, but
to view using one connection per
location.
If you have never attended a Connect
Pro event before, test your connection at
https://collaboration.fda.gov/common/
help/en/support/meeting_test.htm. To
get a quick overview of the Connect Pro
program, visit https://www.adobe.com/
go/connectpro_overview. FDA has
verified the website addresses in this
document, as of the date this document
publishes in the Federal Register, but
websites are subject to change over time.
Transcripts: Please be advised that as
soon as a transcript of the public
workshop is available, it will be
accessible at https://
www.regulations.gov. It may be viewed
at the Dockets Management Staff (see
ADDRESSES). A link to the transcript will
also be available approximately 45 days
after the public workshop on the
internet at https://www.fda.gov/Medical
Devices/NewsEvents/Workshops
Conferences/default.htm. (Select this
public workshop from the posted events
list).
VerDate Sep<11>2014
23:12 Feb 12, 2018
Jkt 244001
Dated: February 8, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–02923 Filed 2–12–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–0180]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Generic Clearance
for the Collection of Quantitative Data
on Tobacco Products and
Communications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on ‘‘Generic
Clearance for the Collection of
Quantitative Data on Tobacco Products
and Communications.’’
DATES: Submit either electronic or
written comments on the collection of
information by April 16, 2018.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before April 16,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of April 16, 2018. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–N–0180 for ‘‘Generic Clearance for
the Collection of Quantitative Data on
Tobacco Products and
Communications.’’ Received comments,
those filed in a timely manner (see
ADDRESSES), will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
E:\FR\FM\13FEN1.SGM
13FEN1
Federal Register / Vol. 83, No. 30 / Tuesday, February 13, 2018 / Notices
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
SUPPLEMENTARY INFORMATION:
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Generic Clearance for the Collection of
Quantitative Data on Tobacco Products
and Communications
OMB Control Number 0910–0810—
Extension
In order to conduct educational and
public information programs relating to
tobacco use as authorized by section
1003(d)(2)(D) of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C.
393(d)(2)(D)), FDA’s Center for Tobacco
Products will create and use a variety of
media to inform and educate the public,
tobacco retailers, and health
professionals about the risks of tobacco
use, how to quit using tobacco products,
and FDA’s role in regulating tobacco.
To ensure that these health
communication messages have the
highest potential to be received,
understood, and accepted by those for
whom they are intended, the Center for
Tobacco Products will conduct research
and studies relating to the control and
prevention of disease. In conducting
such research, FDA will employ
formative pretests. Formative pretests
are conducted on a small scale, and
6191
their focus is on developing and
assessing the likely effectiveness of
communications with specific target
audiences. This type of research
involves: (1) Assessing audience
knowledge, attitudes, behaviors, and
other characteristics for the purpose of
determining the need for and
developing health messages,
communication strategies, and public
information programs and (2) pretesting
these health messages, strategies, and
program components while they are in
developmental form to assess audience
comprehension, reactions, and
perceptions.
Formative pretesting is a staple of best
practices in communications research.
Obtaining voluntary feedback from
intended audiences during the
development of messages and materials
is crucial for the success of every
communication program. The purpose
of obtaining information from formative
pretesting is that it allows FDA to
improve materials and strategies while
revisions are still affordable and
possible. Formative pretesting can also
avoid potentially expensive and
dangerous unintended outcomes caused
by audiences’ interpreting messages in a
way that was not intended by the
drafters. By maximizing the
effectiveness of messages and strategies
for reaching targeted audiences, the
frequency with which tobacco
communication messages need to be
modified should be greatly reduced.
The voluntary information collected
will serve the primary purpose of
providing FDA information about the
perceived effectiveness of messages,
advertisements, and materials in
reaching and successfully
communicating with their intended
audiences. Quantitative testing
messages and other materials with a
sample of the target audience will allow
FDA to refine messages, advertisements,
and materials, including questionnaires
or images, directed at consumers while
the materials are still in the
developmental stage.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
sradovich on DSK3GMQ082PROD with NOTICES
Activity
Number of
responses per
respondent
Total annual
responses
Average burden
per response
Total hours
Screener ...................................................................
Self-Administered Surveys .......................................
130,500
27,000
1
1
130,500
27,000
0.083 (5 minutes) ......
0.33 (20 minutes) ......
10,831
8,910
Total ..................................................................
........................
........................
........................
....................................
19,741
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Sep<11>2014
23:12 Feb 12, 2018
Jkt 244001
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
E:\FR\FM\13FEN1.SGM
13FEN1
6192
Federal Register / Vol. 83, No. 30 / Tuesday, February 13, 2018 / Notices
The number of respondents to be
included in each new survey will vary,
depending on the nature of the material
or message being tested and the target
audience. The burden for this
information collection extension is
proposed to increase by 12,613 hours
since the last OMB approval. The
burden increase is due to an increase in
the number of respondents and the
categories of respondents.
Dated: February 7, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–02852 Filed 2–12–18; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–0409]
Mallinkrodt Pharmaceuticals LLC;
Withdrawal of Approval of an
Abbreviated New Drug Application for
PEMOLINE Tablets, 18.75 Milligrams,
37.5 Milligrams, and 75 Milligrams
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
sradovich on DSK3GMQ082PROD with NOTICES
23:12 Feb 12, 2018
Dated: February 8, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–02925 Filed 2–12–18; 8:45 am]
The Food and Drug
Administration (FDA) is withdrawing
the approval of abbreviated new drug
application (ANDA) 075726 for
PEMOLINE Tablets, 18.75 milligrams
(mg), 37.5 mg, and 75 mg, held by
Mallinkrodt Pharmaceuticals, LLC
(Mallinkrodt). Mallinkrodt requested
withdrawal of this application and has
waived its opportunity for a hearing.
DATES: Approval is withdrawn as of
February 13, 2018.
FOR FURTHER INFORMATION CONTACT:
Kristiana Brugger, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6262,
Silver Spring, MD 20993, 301–796–
3600.
SUPPLEMENTARY INFORMATION: FDA
approved ANDA 075726 for PEMOLINE
Tablets, 18.75 mg, 37.5 mg, and 75 mg,
on March 30, 2001, for the conditions of
use in the labeling of new drug
application (NDA) 016832, the reference
listed drug on which it relied. However,
on October 24, 2005, FDA announced its
concern that the overall liver toxicity
risk of CYLERT (NDA 016832) and
generic pemoline products outweighed
the benefits of these products.
Mallinkrodt and other holders of
approved applications for PEMOLINE
products ceased marketing them at that
SUMMARY:
VerDate Sep<11>2014
time. Indeed, Mallinkrodt stated in its
May 15, 2013, request for withdrawal of
approval of ANDA 075726 that it had
never manufactured or distributed its
product after it received approval of its
application.
In the Federal Register of October 4,
2016 (81 FR 68427), FDA erroneously
included ANDA 075726 in a list of drug
applications for which approval was
being withdrawn under § 314.150(c) (21
CFR 314.150(c)). In a separate notice
published in this issue of the Federal
Register, FDA corrects that notice to
remove ANDA 075726 from the list of
applications whose approval was
withdrawn under § 314.150(c). In
addition, for the reasons discussed
above, and pursuant to Mallinkrodt’s
request, FDA is withdrawing approval
of ANDA 075726, and all amendments
and supplements thereto, under
§ 314.150(d). Distribution of PEMOLINE
Tablets, 18.75 mg, 37.5 mg, and 75 mg,
in interstate commerce without an
approved application is illegal and
subject to regulatory action (see sections
505(a) and 301(d) of the FD&C Act (21
U.S.C. 355(a) and 331(d)).
Jkt 244001
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–E–0780]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; VASCEPA
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for VASCEPA and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of an application to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that human drug
product.
DATES: Anyone with knowledge that any
of the dates as published (in the
SUPPLEMENTARY INFORMATION section) are
incorrect may submit either electronic
or written comments and ask for a
SUMMARY:
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
redetermination by April 16, 2018.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
August 13, 2018. See ‘‘Petitions’’ in the
SUPPLEMENTARY INFORMATION section for
more information.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before April 16,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of April 16, 2018. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
E:\FR\FM\13FEN1.SGM
13FEN1
]]>Agencies
[Federal Register Volume 83, Number 30 (Tuesday, February 13, 2018)]
[Notices]
[Pages 6190-6192]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-02852]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-0180]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Generic Clearance for the Collection of Quantitative
Data on Tobacco Products and Communications
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information, and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on ``Generic Clearance for the Collection of
Quantitative Data on Tobacco Products and Communications.''
DATES: Submit either electronic or written comments on the collection
of information by April 16, 2018.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before April 16, 2018. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of April 16, 2018. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2018-N-0180 for ``Generic Clearance for the Collection of
Quantitative Data on Tobacco Products and Communications.'' Received
comments, those filed in a timely manner (see ADDRESSES), will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information
[[Page 6191]]
redacted/blacked out, will be available for public viewing and posted
on https://www.regulations.gov. Submit both copies to the Dockets
Management Staff. If you do not wish your name and contact information
to be made publicly available, you can provide this information on the
cover sheet and not in the body of your comments and you must identify
this information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Generic Clearance for the Collection of Quantitative Data on Tobacco
Products and Communications
OMB Control Number 0910-0810--Extension
In order to conduct educational and public information programs
relating to tobacco use as authorized by section 1003(d)(2)(D) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393(d)(2)(D)), FDA's
Center for Tobacco Products will create and use a variety of media to
inform and educate the public, tobacco retailers, and health
professionals about the risks of tobacco use, how to quit using tobacco
products, and FDA's role in regulating tobacco.
To ensure that these health communication messages have the highest
potential to be received, understood, and accepted by those for whom
they are intended, the Center for Tobacco Products will conduct
research and studies relating to the control and prevention of disease.
In conducting such research, FDA will employ formative pretests.
Formative pretests are conducted on a small scale, and their focus is
on developing and assessing the likely effectiveness of communications
with specific target audiences. This type of research involves: (1)
Assessing audience knowledge, attitudes, behaviors, and other
characteristics for the purpose of determining the need for and
developing health messages, communication strategies, and public
information programs and (2) pretesting these health messages,
strategies, and program components while they are in developmental form
to assess audience comprehension, reactions, and perceptions.
Formative pretesting is a staple of best practices in
communications research. Obtaining voluntary feedback from intended
audiences during the development of messages and materials is crucial
for the success of every communication program. The purpose of
obtaining information from formative pretesting is that it allows FDA
to improve materials and strategies while revisions are still
affordable and possible. Formative pretesting can also avoid
potentially expensive and dangerous unintended outcomes caused by
audiences' interpreting messages in a way that was not intended by the
drafters. By maximizing the effectiveness of messages and strategies
for reaching targeted audiences, the frequency with which tobacco
communication messages need to be modified should be greatly reduced.
The voluntary information collected will serve the primary purpose
of providing FDA information about the perceived effectiveness of
messages, advertisements, and materials in reaching and successfully
communicating with their intended audiences. Quantitative testing
messages and other materials with a sample of the target audience will
allow FDA to refine messages, advertisements, and materials, including
questionnaires or images, directed at consumers while the materials are
still in the developmental stage.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden per response Total hours
respondents respondent responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Screener.................................... 130,500 1 130,500 0.083 (5 minutes)......................... 10,831
Self-Administered Surveys................... 27,000 1 27,000 0.33 (20 minutes)......................... 8,910
-----------------------------------------------------------------------------------------------------------
Total................................... .............. .............. .............. .......................................... 19,741
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
[[Page 6192]]
The number of respondents to be included in each new survey will
vary, depending on the nature of the material or message being tested
and the target audience. The burden for this information collection
extension is proposed to increase by 12,613 hours since the last OMB
approval. The burden increase is due to an increase in the number of
respondents and the categories of respondents.
Dated: February 7, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-02852 Filed 2-12-18; 8:45 am]
BILLING CODE 4164-01-P
